摘要
目的:评价地洛他定治疗慢性特发性荨麻疹的有效性及安全性。方法:采用多中心、双盲、双模拟阳性对照研究,随机分为试验组和对照组。试验组口服地洛他定,对照组口服氯雷他定,均为1片/次,1次/d,连续服用14d。分别于用药后第1、2周随访,2周末评价疗效与不良反应。结果:入组患者116例,可评价疗效与安全性例数分别为111例和116例。试验组与对照组的总有效率分别为91.23%和90.74%(P>0.05)。两组的不良反应发生率分别为20.69%和16.36%(P>0.05)。结论:地洛他定治疗慢性特发性荨麻疹安全、有效,与氯雷他定相当。
Objective: To study the efficacy and safety of desloratadine in chronic idiopathic urticaria (CIU). Methods: This study was a randomized, double-blind, double-analog comparative muhicenter trial of 2 weeks'duration. Patients were randomly allocated to receive either desloratadine (n =58) or loratadine one tablet (n=58) once-daily for 14 days, and followed up at 7th day and 14th day after treatment. Results: Of the 116 patients who enrolled the study, 111 cases and 116 cases could be evaluated the efficacy and safety respectively. The total response rates of desloratadine and loratadine were 91.23% and 90.74% , respectively (P〉0.05). The adverse reactions rates were 20.69% and 16.36% (P〉0.05). Conclusion: Both desloratadine and loratadine are well tolerated and effective in the treatment of CIU.
出处
《山东大学学报(医学版)》
CAS
北大核心
2005年第9期842-844,共3页
Journal of Shandong University:Health Sciences